Table S1. Comparison of patients' characteristics treated or not with lenalidomide before treatment with KRd in real life.

	Previous Exposure to Lenalidomide (*n* = 53) Group A	No Previous Exposure to Lenalidomide (*n* = 77) Group B	*p*-Value
Median age, years (range)	65 (45–86)	64 (33–78)	0.92
Males, *n* (%)	30 (57%)	43 (56%)	0.98
Paraproteins (isotype), *n* (%)			
Immunoglobulin G	33 (62%)	45 (59%)	0.92
Immunoglobulin A	11 (21%)	13 (17%)	0.88
Immunoglobulin M	1 (2%)	1 (1%)	0.96
Light chain only	8 (15%)	16 (21%)	0.75
Not secretory	0 (0%)	2 (2%)	0.65
FISH			
failed- or not evaluable	28 (53%)	38 (49%)	0.78
Standard risk	15 (28%)	30 (39%)	***0.02***
High-risk	10 (19%)	9 (12%)	***0.02***
ISS stage			
I	36 (68%)	45 (58%)	***0.02***
II	9 (17%)	16 (21%)	***0.02***
III	8 (15%)	16 (21%)	***0.02***
Previous treatments			
Single autologous SCT	15 (28%)	25 (32%)	0.87
Double autologous SCT	17 (32%)	23 (30%)	0.92
Median of prior treatments	2 (1–10)	1 (1–7)	***0.0001***

Table S2. Comparison of patients' characteristics treated or not with pomalidomide before treatment with KRd in real life.

	Previous Exposure to Pomalidomide (*n* = 16)	No Previous Exposure to Pomalidomide (*n* = 114)	*p*-Value
Median age, years (range)	68 (52–77)	64 (33–86)	***0.03***
Males, n (%)	9 (56%)	64 (56%)	0.89
Paraproteins (isotype), n (%)			
Immunoglobulin G	6 (38%)	69 (61%)	***0.03***
Immunoglobulin A	3 (19%)	23 (20%)	0.89
Light chain only	7 (43%)	22 (19%)	***0.02***
FISH			
failed-not evaluable	13 (81%)	85 (75%)	0.89
del13q	0 (0%)	1 (0.9%)	0.91
t4,14 or t 11,14	1 (6%)	9 (8.1%)	0.88
del17p	2 (12%)	3 (26%)	0.72
No alterations identified	0 (0%)	16 (14%)	0.03
ISS stage			
I	9 (56%)	72 (63%)	0.23
II	4 (25%)	21 (18%)	0.22

III			3 (19%)		21 (18%)		0.89		
Previous treatment									
Single autologous SCT			6 (38%)		34 (30%)		*0.06*		
Double autologous SCT			2 (13%)		38 (33%)		*0.04*		
Median of prior treatments			4 (1–10)		2 (1–7)		*0.0001*		

Table S3 Univariate and multivariate analysis of PFS and OS in 21 patients who completed at least 18 cycles of KRd.

			Univariate Analysis		Multivariate Analysis		Univariate Analysis		Multivariate Analysis	
		n	PFS @ 24 moNths	*p*-value	HR (95% CI)	*p*-Value	OS @ 24 Months	*p*-Value	HR (95% CI)	*p*-Value
Age	<=65	7	94.1	0.3			93.7	0.19		
	>65	14	57.6				77.9			
Gender	male	11	90.5	0.08			90.5	0.45		
	female	10	57.8				77.8			
ISS	I-II	14	8.5	0.33			91.3	0.15		
	III	7	71.4				71.4			
Prior lines	1, 2	14	84.1	0.052			95.5	*0.004*		
	more than 2	7	57.1				57.1			
Previous lenalidomide	no	4	98.0	0.09			98.0	0.21		
	yes	17	69.4				81.7			
Previous pomalidomide	no	20	78	0.62			86.2	0.70		
	yes	1	100				100			
Previous BMT	no	6	44.4	*0.01*			77.8	0.33		
	yes	15	90.7				90.4			
Zoledronic acid exposure	no	5	75.0	0.48			87.5	0.98		
	yes	16	81.0				86.1			
Relapse	biochemical	6	83.3	0.96			83.3	0.64		
	clinical	15	78.0				87.7			
ClCr	<30 ml/min	6	33.3	*<0.0001*	22 (2.5-202.3)	*0.006*	33.3	*<0.0001*	na	
	>30ml/min	15	90.4				98.2			
K Cumulative dose (2 cycles)	<310mg/mq	7	78.6	0.65			85.4	0.83		
	>310mg/mq	14	88.9				87.5			
Best response	<VGPR	8	76.2	0.92			85.7	0.94		
	CR+VGPR	13	80.0				86.7			